10-K: Petros Pharmaceuticals Faces Going Concern Uncertainty Despite Intangible Asset Review

Petros Pharmaceuticals reports a net loss of $8.2 million for 2023 and expresses substantial doubt about its ability to continue as a going concern, despite efforts to expand Stendra sales and pursue OTC approval.

Summary

• Petros Pharmaceuticals reported a net loss of $8.2 million for the year ended December 31, 2023, compared to a net loss of $20.0 million in 2022.
• The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern due to recurring losses and insufficient liquidity.
• Petros had approximately $13.3 million in cash as of December 31, 2023, but needs to raise additional capital to fund operations.
• The company's revenue was $5.8 million in 2023, with $2.3 million from prescription medications (primarily Stendra) and $3.5 million from medical devices.
• Petros is pursuing an over-the-counter (OTC) designation for Stendra, which it believes has the potential to dramatically increase product sales.
• The company recorded a significant intangible asset impairment charge related to Stendra in 2022, and may need to record additional charges if revenue projections are not met.
• Three customers accounted for approximately 60% of Petros' consolidated gross billings in 2023, and four main customers accounted for 93% of Stendra gross billings.
• Petros is subject to ongoing obligations under a settlement agreement with Vivus, including a promissory note of $10.2 million, with a remaining balance of $8.0 million as of December 31, 2023.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including a going concern warning and substantial losses, which overshadow any positive developments. The need for a capital raise and the uncertainty surrounding the OTC approval process contribute to a negative outlook.

Positives

• The net loss decreased significantly from $20.0 million in 2022 to $8.2 million in 2023.
• The company is actively pursuing an OTC designation for Stendra, which could significantly increase sales.
• Petros has a technology transfer agreement with Patheon for commercial production of Stendra tablets.
• The company has distribution agreements with major pharmaceutical distributors.
• Petros has a growing network of distributors for its VED products.

Negatives

• The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern.
• Petros has incurred significant losses and negative cash flows from operations since its inception.
• The company is dependent on a limited number of customers for a significant portion of its sales.
• Petros is subject to ongoing obligations under a settlement agreement with Vivus, including a promissory note.
• The company may need to record additional impairment charges if revenue projections for Stendra are not met.
• Petros has identified material weaknesses in its internal control over financial reporting.

Risks

• Petros may not be able to raise sufficient capital to fund its operations.
• The company's OTC strategy for Stendra may not be successful.
• Petros is dependent on a limited number of customers, and the loss of any of these customers could have a material adverse effect.
• The company may experience delays or problems in the supply of Stendra if Patheon experiences manufacturing issues.
• Petros may face pricing pressure on its products due to social or political pressure to lower drug costs.
• The company may face competition from generic drug products and other similar drug products.
• Petros is subject to ongoing obligations under a settlement agreement with Vivus.
• Cyberattacks and other data security breaches could compromise the company's proprietary and confidential information.
• The company's stock price may be volatile.

Future Outlook

Petros expects to continue to invest in its operations and product development to maintain and grow its current market position and to meet its expanded reporting and compliance obligations as a public company. The company is focused on expanding its service offering through internal development, collaborations, and through strategic acquisitions. Petros is also exploring additional ways to raise capital, but there is no assurance that it will be able to raise capital.

Management Comments

• Petros is committed to the goal of becoming a leading innovator in the emerging self-care market driving expanded access to key prescription pharmaceuticals as Over-the-Counter treatment options.
• Petros believes that its potential growth will come through the expansion of its distribution partner network.
• Petros intends to continue to leverage existing relationships with key clinician decision makers, offering direct purchase agreements for Centers of Excellence in prostate cancer and sexual health rehabilitation.

Industry Context

The oral ED market, specifically the PDE-5 inhibitor class, has experienced significant growth, with future market estimates reflecting similar trends. Stendra remains the only patent-protected brand among the PDE-5 inhibitor class. The market is projected to continue to grow at a Compounded Annual Growth Rate of 7.1% through 2028, with North America expected to remain the lead market.

Comparison to Industry Standards

• The document notes that generic options like sildenafil (generic Viagra) and tadalafil (generic Cialis) have led growth in prescription volume, indicating a competitive landscape where branded products face pricing pressure.
• Petros' reliance on a limited number of customers is a common risk for smaller pharmaceutical companies, but the concentration of 93% of Stendra gross billings with four main customers is higher than ideal.
• The company's pursuit of OTC status for Stendra is a strategic move to differentiate itself from generic competitors, but the regulatory pathway is complex and uncertain.
• The company's financial performance is below industry benchmarks for profitability and cash flow, as evidenced by the going concern warning from its auditor.
• The company's reliance on third-party manufacturers is a common practice in the pharmaceutical industry, but the potential for delays or problems in the supply chain is a significant risk.

Legal Proceedings

• The company is involved in various legal matters arising in the normal course of business, but does not expect the outcome of such proceedings to have a material effect on its financial position.

Related Party Transactions

• In connection with the Private Placement, the company issued to Alto Opportunity Master Fund, SPC Segregated Master Portfolio B (Alto) 1,000 shares of its Series A Preferred Stock and Warrants to purchase up to 444,444 shares of common stock, which beneficially owns more than 5% of our voting securities, for aggregate gross proceeds of $1 million.
• On November 28, 2023, the Board approved a payment to JCP III AIV of $125,000 in recognition of various management and advisory services previously provided to the Company by JCP III AIV.

Stakeholder Impact

• Shareholders face the risk of dilution from potential capital raises and the uncertainty of the company's future.
• Employees may be affected by potential cost-cutting measures or restructuring if the company's financial situation does not improve.
• Customers may experience disruptions in product availability if the company faces manufacturing or supply chain issues.
• Suppliers and creditors face the risk of non-payment if the company's financial situation deteriorates further.

Next Steps

• Petros will continue to pursue the OTC switch for Stendra.
• The company will explore additional ways to raise capital.
• Petros will continue to invest in its operations and product development.
• The company will continue to work with Patheon for commercial production of Stendra tablets.

Key Dates

Keywords

Petros Pharmaceuticals, Stendra, Erectile Dysfunction, OTC, Pharmaceuticals, Medical Devices, Financial Results, Going Concern, Intangible Assets, Capital Raise